Niagen Bioscience shares are trading up 2.54% at $13.75 at the time of this writing on Thursday morning. Since the current price is $13.75, this makes Cohen's 0 shares worth $0.

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical ...

COIN and CRCLE are some of the US crypto stocks surging after the GENIUS Act passed, signaling strong growth in the crypto ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives Academy; Drive Growth with Insights ... (RTTNews) - PASSAGE BIO, INC. (PASG) revealed Loss for full year of -$64.77 million.

Passage Bio (NASDAQ:PASG – Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.21 ...

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Passage Bio CFO sells shares worth $1,685. Kathleen Borthwick, the Chief Financial Officer of Passage BIO, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company currently valued at $32. ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transition, ...

Passage Bio, Inc., a biotechnology firm specializing in biological products, has transferred its stock listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.